选择性磷酸二酯酶5抑制剂治疗阴茎勃起功能障碍的临床评价

Efficacy of Selective Inhibitors of Phosphodiesterase-5 (PDE-5) for Erectile Dysfunction:A Clinical Evaluation

目的:选择性磷酸二酯酶5(PDE-5)抑制剂在勃起功能障碍的治疗中占有重要地位,西地那非、伐地那非以及他达拉非是目前在临床治疗中广泛应用的3种药物,而三者在勃起功能障碍治疗中的效果及不良反应上的差异日益引起了人们的关注。本文对这3种药物治疗的有效性及安全性进行了总结和评价。方法:收集3种药物的作用机制、药动学特点、起效时间与维持时间、治疗有效率及药物不良反应的临床研究证据,对国内外相关研究文献进行综述。结果及结论:3种药物均高度有效,但目前还没有可靠的临床证据表明某一种药物的"优越性",尚需更多的随机对照研究加以确证。

OBJECTIVE： Selective PDE - 5 inhibitors play an important role in the treatment of erectile dysfunction. Sildenafil, vardenafil and tadenafil are widely used PDE - 5 inhibitors in clinical treatment of erectile dysfunction. However, their differences in efficacy and safety have become the focus of attention. This paper summarized and evaluated the efficacy and safety of the above 3 drugs. METHODS： The clinical evidences on the study of the action mechanism, pharmacokinetics, the efficacy, onset time and duration of the action, effective rate and related adverse events of the 3 drugs were collected and the pertinent literature both at home and abroad was reviewed. RESULTS ＆ CONCLUSION： All the three drugs are highly effective yet no reliable evidence is available to prove which one is superior to the others, which still requires more randomized controlled studies to confirm.